Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
luke.steventon@ndph.ox.ac.uk

Research groups

Benefits and Risks of Cancer Treatments

Luke Steventon

Visiting PhD Student

Luke is a researcher at University College London Hospital and a part-time PhD student at the University College London School of Pharmacy. He collaborates with the Benefits and Risks of Cancer Treatment team in Oxford Population Health on studies of outcomes after chemotherapy. His PhD studies focus on treatment effects of systemic therapies for gynaecological cancers. Other research activities include the development of a predictive model of renal and hepatic function for patients on chemotherapy, the impact of chemotherapy delays on survival outcomes, and management of a quality improvement project aiming to widen access to bispecific antibodies for myeloma patients.